research Human hair follicles display a functional equivalent of the hypothalamic‐pituitary‐adrenal (HPA) axis and synthesize cortisol
Human hair follicles can produce cortisol like the body's stress response system.
Search
forResearch
5 / 1000+ results
research Sex differences in the hypothalamic–pituitary–adrenal axis’ response to stress: an important role for gonadal hormones
Male and female bodies respond differently to stress, influenced by hormones and development stages, with implications for stress-related diseases.
research Expression of Hypothalamic–Pituitary–Thyroid Axis RelatedGenes in the Human Skin
Thyroid-related genes are active in skin cells and may affect autoimmune conditions.
research Maternal Influence on Child HPA Axis: A Prospective Study of Cortisol Levels in Hair
Maternal stress during pregnancy affects a child's stress levels.
research Hypothalamic–Pituitary–Thyroid Axis Hormones Stimulate Mitochondrial Function and Biogenesis in Human Hair Follicles
HPT axis hormones boost mitochondrial function and growth in hair follicles, potentially aiding hair health.
Clinics
1 / 41 results
Community Join
3 / 1000+ resultscommunity CB-03-01 / Breezula Personal Results
The user shared their experience with CB-03-01 (Breezula/Clascoterone) for hair loss, noting reduced shedding and improved hair appearance but experiencing significant sleep disturbances and low energy due to HPA axis suppression. They decided to stop using it due to these side effects and are waiting for GT20029 as an alternative.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.
community There’s actually a quite good chance that next year, we might see a new treatment get FDA approval for the first time in nearly three decades.
Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.
Learn
— no results
Experts
— no results